Free Newsletter
Researchers solve failed RSV vax mystery
Researchers have finally figured out why a respiratory syncytial virus vaccine used in 1966 to innoculate children against the infection failed and caused severe respiratory disease. The team, led by Johns Hopkins Children's Center, says antibodies in the vax would not bind to the virus, and thus failed to trigger an immune response. Trials conducted with mice revealed that the vaccine produced a stronger response after being infused with a substance that produced antibodies better equipped to bind to the virus and neutralize it. The results of the initial innoculation attempt effectively halted research on killed-virus vaccines, but these new findings could be the kickstart needed to get that research going again.
"We have found the root cause of the problem, and in doing so we have uncovered clues that will help us design even safer and more effective vaccines in the future," says senior investigator Fernando Polack, M.D., an infectious disease specialist at Hopkins Children's.
- check out the release for more
Related Articles:
Alnylam gains on positive mid-stage RSV data
MedImmune's new RSV drug faces delay
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




